# First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979

> **NCT02509117** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 55 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** PF-06751979 single ascending dose
- **DRUG:** Placebo single dose
- **DRUG:** PF-06751979 multiple ascending dose
- **DRUG:** Placebo multiple dose
- **DRUG:** PF-06751979 multiple dose
- **DRUG:** PF-06751979 multiple dose

## Key facts

- **NCT ID:** NCT02509117
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2018-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02509117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02509117, "First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02509117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*